Literature DB >> 9733519

Prevention of cardiac hypertrophy in mice by calcineurin inhibition.

M A Sussman1, H W Lim, N Gude, T Taigen, E N Olson, J Robbins, M C Colbert, A Gualberto, D F Wieczorek, J D Molkentin.   

Abstract

Hypertrophic cardiomyopathy (HCM) is an inherited form of heart disease that affects 1 in 500 individuals. Here it is shown that calcineurin, a calcium-regulated phosphatase, plays a critical role in the pathogenesis of HCM. Administration of the calcineurin inhibitors cyclosporin and FK506 prevented disease in mice that were genetically predisposed to develop HCM as a result of aberrant expression of tropomodulin, myosin light chain-2, or fetal beta-tropomyosin in the heart. Cyclosporin had a similar effect in a rat model of pressure-overload hypertrophy. These results suggest that calcineurin inhibitors merit investigation as potential therapeutics for certain forms of human heart disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733519     DOI: 10.1126/science.281.5383.1690

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  108 in total

1.  Making matters worse for a broken heart.

Authors:  N Frey; E N Olson
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

Authors:  C Nataraj; M I Oliverio; R B Mannon; P J Mannon; L P Audoly; C S Amuchastegui; P Ruiz; O Smithies; T M Coffman
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 3.  Meeting Koch's postulates for calcium signaling in cardiac hypertrophy.

Authors:  K R Chien
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 4.  Calcineurin inhibition and cardiac hypertrophy: a matter of balance.

Authors:  L A Leinwand
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 5.  Endoplasmic reticulum in the heart, a forgotten organelle?

Authors:  N Mesaeli; K Nakamura; M Opas; M Michalak
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

6.  Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes.

Authors:  N H Purcell; G Tang; C Yu; F Mercurio; J A DiDonato; A Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

Review 7.  Medical treatment of hypertrophic cardiomyopathy.

Authors:  M V Sherrid; D Gunsburg; A Sharma
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

8.  O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.

Authors:  Heberty T Facundo; Robert E Brainard; Lewis J Watson; Gladys A Ngoh; Tariq Hamid; Sumanth D Prabhu; Steven P Jones
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-09       Impact factor: 4.733

9.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.

Authors:  T Taigen; L J De Windt; H W Lim; J D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 10.  Antihypertensive drugs and the heart.

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.